This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Karlowsky, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Karlowsky, J. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2002, p. 669-674, Vol. 40, No. 2
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.2.669-674.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations

Daniel F. Sahm,1 Clyde Thornsberry,2 David C. Mayfield,1 Mark E. Jones,3 and James A. Karlowsky1*

Focus Technologies, Inc., Herndon, Virginia 20171,1 Focus Technologies, Inc., Franklin, Tennessee 37064,2 Focus Technologies, Inc., 1217 KP Hilversum, The Netherlands3

Received 28 September 2001/ Returned for modification 8 November 2001/ Accepted 26 November 2001

Publication of the NCCLS M100-S12 document in January 2002 introduced ceftriaxone and cefotaxime MIC interpretative breakpoints of <=1 µg/ml (susceptible), 2 µg/ml (intermediate), and >=4 µg/ml (resistant) for nonmeningeal isolates of Streptococcus pneumoniae. To estimate the effect of these breakpoint changes on clinical laboratory susceptibility testing results, nonmeningeal pneumococcal isolate (blood and respiratory) data from The Surveillance Network Database-USA, an electronic surveillance database, for the years 1996 to 2000 were collated and studied. Of 9,863 nonmeningeal isolates tested against ceftriaxone, 82.7% were susceptible, 13.2% were intermediate, and 4.1% were resistant by the M100-S11 NCCLS breakpoints (2001); by M100-S12 breakpoints, 95.9% of the isolates were susceptible, 3.1% were intermediate, and 1.0% were resistant. Of 10,777 nonmeningeal isolates tested against cefotaxime, 79.2% were susceptible, 14.3% were intermediate, and 6.5% were resistant by M100-S11 breakpoints; by M100-S12 breakpoints, 93.5% were susceptible, 4.2% were intermediate, and 2.3% were resistant. Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints for nonmeningeal isolates of S. pneumoniae decreased the number of isolates interpreted as intermediate by 10% and as resistant by 3 to 4%.

* Corresponding author. Mailing address: Focus Technologies, Inc., 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2575. Fax: (703) 480-2654. E-mail: jkarlowsky{at}focusanswers.com.

Journal of Clinical Microbiology, February 2002, p. 669-674, Vol. 40, No. 2
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.2.669-674.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Su, L.-H., Wu, T.-L., Kuo, A.-J., Chia, J.-H., Chiu, C.-H. (2009). Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J Antimicrob Chemother 64: 336-342 [Abstract] [Full Text]  
  • Gums, J. G, Boatwright, D W., Camblin, M., Halstead, D. C, Jones, M. E, Sanderson, R. (2008). Differences Between Ceftriaxone and Cefotaxime: Microbiological Inconsistencies. The Annals of Pharmacotherapy 42: 71-79 [Abstract] [Full Text]  
  • Karlowsky, J. A., Jones, M. E., Draghi, D. C., Sahm, D. F. (2003). Clinical Isolates of Streptococcus pneumoniae with Different Susceptibilities to Ceftriaxone and Cefotaxime. Antimicrob. Agents Chemother. 47: 3155-3160 [Abstract] [Full Text]  
  • Karlowsky, J. A., Jones, M. E. (2003). Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae. J Antimicrob Chemother 51: 467-468 [Full Text]  
  • Jones, R. N., Mutnick, A. H., Varnam, D. J. (2002). Impact of Modified Nonmeningeal Streptococcus pneumoniae Interpretive Criteria (NCCLS M100-S12) on the Susceptibility Patterns of Five Parenteral Cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001). J. Clin. Microbiol. 40: 4332-4333 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»